** A groundbreaking film-coated tablet, Linerixibat, is now a lifeline for adults battling relentless itchiness caused by primary biliary cholangitis.
📍 ** United Kingdom, London
**
The British Medicines Agency, MHRA, has greenlit Linerixibat (Lynavoy), a revolutionary new treatment targeting the frustrating symptoms of primary biliary cholangitis (PBC). This chronic condition, notorious for damaging bile ducts and causing a toxic build-up of bile acids, has long been a challenge for patients. Linerixibat directly tackles this problem, reducing the harmful substances in the body and ultimately, dramatically lessening the debilitating itch. The news marks a significant step forward, offering a much-needed treatment option where previously few existed.
The journey to approval was backed by robust clinical trial data, namely the "Glisten" study. Researchers recruited 238 patients with PBC and meticulously tracked their experience over 24 weeks, comparing Linerixibat (40mg twice daily) with a placebo. The results were decisive: patients on Linerixibat experienced a statistically significant reduction in their itch intensity, and importantly, reported a substantial improvement in sleep disruption—a common and devastating consequence of chronic itching.
The MHRA’s approval reflects a commitment to patient wellbeing, with Julian Beach, Interim Executive Director of Healthcare Quality and Access, emphasizing ongoing vigilance. Patients and healthcare professionals are encouraged to report any side effects via the MHRA’s Yellow Card scheme, safeguarding the continued safety and efficacy of this potentially life-changing medication.
**
Original Source: Link
** #PBC #PrimaryBiliaryCholangitis #ItchRelief #MHRA #Lynavoy #DrugApproval #ChronicIllness #PatientCare